Baritaki Stavroula, Huerta-Yepez Sara, Cabrava-Haimandez Ma da Lourdas, Sensi Marialuisa, Canevari Silvana, Libra Massimo, Penichet Manuel, Chen Haiming, Berenson James R, Bonavida Benjamin
Department of Microbiology, Immunology and Molecular Genetics, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, CA.
For Immunopathol Dis Therap. 2011 Apr 1;2(2). doi: 10.1615/ForumImmunDisTher.v2.i2.90.
Multiple myeloma (MM) is the second most common hematological and incurable malignancy of plasma cells with low proliferative activity in the bone marrow. MM patients initially respond to conventional therapy, however, many develop resistance and recurrences occur. We have identified RKIP as a novel gene product that is differentially overexpressed in MM cell lines and MM tissues compared to other studied tumors and normal bone marrow. This overexpression consisted, in large part, of a phosphorylated inactive form of RKIP at Ser153 (p-Ser153 RKIP). In contrast to RKIP, p-Ser153 RKIP lacks its ability to inhibit the MAPK signaling pathway. The overexpression of p-Ser153 RKIP in MM cell lines and MM tissues was further validated in a mouse model carrying a human MM xenograft, namely, LAGλ-1B. Bioinformatic analyses from databases support the presence of increased RKIP mRNA expression in MM compared to normal plasma cells. In these databases, high RKIP levels in MM are also correlated with the nonhyperdiploid status and the presence of IgH translocations, parameters that generally display more aggressive clinical features and shorter patients' survival irrespective of the treatment. Since RKIP expression regulates both the NF-κB and MAPK survival pathways, the overexpression of "inactive" p-Ser153 RKIP in MM might contribute positively to the overall cell survival/antiapoptotic phenotype and drug resistance of MM through the constitutive activation of survival pathways and downstream the transcription of anti-apoptotic gene products. The overexpression of RKIP and p-Ser153 RKIP in MM is the first demonstration in the literature, since in most tumor tissues the expression of RKIP is very low and the expression of p-Ser153 RKIP is much lower. The relationship between the levels of active RKIP and inactive p-Ser153 RKIP in MM may be of prognostic significance, and the regulation of RKIP activity may be a target for therapeutic intervention.
多发性骨髓瘤(MM)是第二常见的血液系统恶性肿瘤,是一种无法治愈的骨髓浆细胞恶性肿瘤,其增殖活性较低。MM患者最初对传统疗法有反应,然而,许多患者会产生耐药性并复发。我们已确定RKIP是一种新型基因产物,与其他研究的肿瘤和正常骨髓相比,它在MM细胞系和MM组织中差异过表达。这种过表达在很大程度上由Ser153位点磷酸化的无活性形式的RKIP(p-Ser153 RKIP)组成。与RKIP相反,p-Ser153 RKIP缺乏抑制MAPK信号通路的能力。在携带人MM异种移植瘤的小鼠模型即LAGλ-1B中,进一步验证了p-Ser153 RKIP在MM细胞系和MM组织中的过表达。来自数据库的生物信息学分析支持与正常浆细胞相比,MM中RKIP mRNA表达增加。在这些数据库中,MM中高RKIP水平也与非超二倍体状态和IgH易位的存在相关,这些参数通常显示出更具侵袭性的临床特征且患者生存期较短(无论治疗情况如何)。由于RKIP表达调节NF-κB和MAPK生存途径,MM中“无活性”的p-Ser153 RKIP的过表达可能通过生存途径的组成性激活以及抗凋亡基因产物转录的下游过程,对MM的整体细胞存活/抗凋亡表型和耐药性产生积极影响。MM中RKIP和p-Ser153 RKIP的过表达是文献中的首次证明,因为在大多数肿瘤组织中RKIP表达非常低,而p-Ser153 RKIP的表达更低。MM中活性RKIP和无活性p-Ser153 RKIP水平之间的关系可能具有预后意义,并且调节RKIP活性可能是治疗干预的一个靶点。